Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P598: Adherence to treatment in IBD: to see beyond motivationECCO '18 Vienna
Year: 2018
Authors:

J. Poza Cordon1*, C. Suarez Ferrer2,3, O. Crivillen Anguita3, E. Martin Arranz1, M. Jaquotot Herranz1, S. Gomez Senent1, M.D. Martin Arranz1

1Hospital Universitario La Paz, Department of Gastroenterology, Madrid, Spain, 2Hospital Universitario la paz, Radiology, Madrid, Spain, 3Hospital Universitario la paz, Gastroenterology, Madrid, Spain

P599: Short- and long-term outcome of minimally invasive approach for Crohn’s disease: Comparison between single incision, robotic-assisted and conventional laparoscopyECCO '18 Vienna
Year: 2018
Authors:

D. Zambonin1*, F. Giudici1, F. Ficari1, F. Rogai2, S. Scaringi3

1University of Florence, Florence, Italy, 2Division of Gastroenterology, AOU Careggi Hospital, Department of Emergency, Florence, Italy, 3Digestive Surgery Unit, Careggi University Hospital, Department of Surgery and Translational Medicine, Florence, Italy

P600: Clinical utility of anti-IFI16 seroreactivity in the response to anti-TNF therapy in IBDECCO '18 Vienna
Year: 2018
Authors:

V. Caneparo1,2, B. Verstockt3,4, S. Vermeire3,4, S. Landolfo1, M. Gariglio2, M. De Andrea1,2*

1University of Turin, Medical School, Department of Public Health and Pediatric Sciences, Viral Pathogenesis Unit, Turin, Italy, 2University of Piemonte Orientale, Department of Translational Medicine, Virology Unit, Novara, Italy, 3University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 4Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

P601: Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST studyECCO '18 Vienna
Year: 2018
Authors:

R. Panaccione1*, R. Atreya2, M. Ferrante3, M.C. Dubinsky4, B.E. Sands4, M.T. Abreu5, F. Cataldi6, J.V. Enejosa6, Q. Zhou6, B. Huang6, A.P. Lacerda6, A.L. Pangan6

1University of Calgary, Calgary, Canada, 2Friedrich-Alexander-University Erlangen-Nürnberg, Medical Clinic 1, Erlangen, Germany, 3University Hospitals Leuven, Leuven, Belgium, 4Icahn School of Medicine at Mount Sinai, New York, USA, 5University of Miami, Miami, USA, 6AbbVie Inc., North Chicago, USA

P602: Factors associated with discontinuation of initial and subsequent tumour necrosis factor inhibitors in a large paediatric inflammatory bowel disease observational cohortECCO '18 Vienna
Year: 2018
Authors:

J. Kaplan1,2*, C. Liu3, E. King3, J. Bass4, A. Patel5, G. Tomer6, J. Tung7, J. Pratt3, S. Chen3, T. Lissoos8, R. Colletti9, ImproveCareNow Network

1MassGeneral Hospital for Children, Pediatric Gastroenterology, Boston, USA, 2Harvard Medical School, Boston, USA, 3Cincinnati Children's Hospital, Cincinnati, USA, 4Children’s Mercy Hospital, Kansas City, USA, 5University of Texas-Southwestern/Children's Medical Center, Dallas, USA, 6The Children’s Hospital at Montefiore, Bronx, USA, 7Mayo Clinic-Children’s Center, Rochester, USA, 8Takeda Pharmaceuticals USA, Deerfield, USA, 9University of Vermont College of Medicine, Burlington, USA

P603: Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

J. Hanžel1*, N. Sever1, I. Ferkolj1, B. Štabuc1, N. Smrekar1, M. Koželj1, G. Novak1, A. Gils2, D. Drobne1

1University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia, 2KU Leuven, Laboratory of Pharmaceutical Biology, Leuven, Belgium

P604: Interest in the addition of azathioprine (AZA) to the switch of anti-TNF in IBD patients in loss of response with undetectable anti-TNF trough levels and anti-drug antibodies: A prospective randomised trialECCO '18 Vienna
Year: 2018
Authors:

X. Roblin1*, S. Paul2, G. Boschetti3, J.M. Phelip4, E. Del Tedesco4, A. Berger5, S. Nancey3, N. Williet6, B. Flourie3

1Gastroneterology Unit, Saint Etienne, France, 2University of Saint Etienne, Immunology, Saint Etienne, France, 3University of Lyon, Lyon, France, 4University Hospital, Gastroenterology, Saint Etienne, France, 5Saint Etienne University, Saint Etienne, France, 6CHU Saint Etienne, Saint Etienne, France

P605: Transanal minimally invasive proctectomy (TaMIP) in patients with Crohn’s disease: A cohort study from the TaTME international databaseECCO '18 Vienna
Year: 2018
Authors:

G. Pellino1,2*, K. Sahnan2,3, M. Penna3,4, S. Adegbola2,3, P. Chandrasinghe2,3,5, R. Hompes4, A. Spinelli6,7, J. Warusavitarne2,3, on behalf of the International TaTME Registry Collaborative

1Università della Campania, Unit of Colorectal Surgery, Naples, Italy, 2St Mark's Hospital, Fistula Research Unit, London, UK, 3Imperial College, Department of Surgery and Cancer, London, UK, 4Oxford University Hospital NHS Trust - Churchill Hospital, Department of Colorectal Surgery, Oxford, UK, 5Faculty of Medicine, University of Kelaniya, Department of Surgery, Kelaniya, Sri Lanka, 6Humanitas University, Colon and Rectal Surgery Unit, Department of General Surgery, Rozzano, Italy, 7Humanitas University, Humanitas University, Department of Biomedical Sciences, Rozzano, Italy

P606: Health-related utility weights in Crohn's disease patients with perianal fistulaECCO '18 Vienna
Year: 2018
Authors:

L. Longworth1*, D. Fountain1, J. Singh1, I. Azzabi2, G. Owen3

1PHMR Ltd., London, UK, 2Takeda Pharmaceuticals International GmbH, Zurich, Switzerland, 3Takeda UK Ltd., High Wycombe, UK

P607: Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patientsECCO '18 Vienna
Year: 2018
Authors:

S. Fischer1*, E. Klenske1, H. Schmitt1, F. Vitali1, S. Hirschmann1, F. Koch1, A. Ramming2, S. Zundler1, D. Nagore3, W. Uter4, M.F. Neurath1, R. Atreya1

1Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine 1, Erlangen, Germany, 2Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine 3, Erlangen, Germany, 3Progentica Biopharma, Derio, Spain, 4Friedrich-Alexander University Erlangen-Nürnberg, Department of Medical Informatics, Biometry and Epidemiology, Erlangen, Germany

P608: IV iron treatment of iron deficiency anaemia with ferumoxytol in patients with inflammatory bowel disease unable to take oral iron: A randomised controlled trial vs. ferric carboxymaltoseECCO '18 Vienna
Year: 2018
Authors:

W. Strauss*, N. Dahl, J. Jiang, K. Bernard, R. Kaper, J. Krop

AMAG Pharmaceuticals, Inc., Waltham, USA

P609: Uncertain usefulness of infliximab trough levels for therapeutic decision-making in inflammatory bowel disease patients on infliximab maintenance therapyECCO '18 Vienna
Year: 2018
Authors:

F. Cañete1,2*, T. Lobatón2, E. Cabré2,3, M. Mañosa2,3, A. Teniente4, A. Clos2, P. Torres2, G. Valldosera2, E. Martínez-Cáceres4, E. Domènech2,3

1Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Barcelona, Spain, 2Hospital Universitari Germans Trias i Pujol, Department of Gastroenterology, Badalona, Barcelona, Spain, 3CIBEREHD, Madrid, Spain, 4Hospital Universitari Germans Trias i Pujol, Department of Immunology, Badalona, Barcelona, Spain

P610: Risk of active Hepatitis B and C infections in the Phases 2 and 3 clinical trial programmes for ustekinumabECCO '18 Vienna
Year: 2018
Authors:

R. Gish1, P. Ramachandran2, W. Xu2, S. Sloan2*

1Stanford Medical Center, Stanford, USA, 2Janssen Research and Development, LLC, Spring House, USA

P611: Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre studyECCO '18 Vienna
Year: 2018
Authors:

A. Viola1*, D. Pugliese2, S. Renna3, F. Furfaro4, F. Caprioli5, R. D'Inca'6, F. Bossa7, G. Costantino1, M. Fantini8, G. Fiorino4, A. Armuzzi2, A. Orlando3, W. Fries1

1University of Messina, IBD-unit, Department of Clinical and Experimental Medicine, Messina, Italy, 2Catholic University, IBD Unit Complesso Integrato Columbus, Fondazione Policlinico Gemelli, Rome, Italy, 3University of Palermo, "Villa Sofia-Cervello" Hospital, Di.Bi.M.I.S., Division of Internal Medicine, Palermo, Italy, 4Humanitas Research Hospital, Rozzano, IBD Center, Department of Gastroenterology, Milan, Italy, 5Ospedale Maggiore Policlinico, Milan, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Grande, Milano, Italy, 6University of Padua, Gastroenterology Unit, Department of Surgical, Oncological, and Gastroenterological Sciences, Padova, Italy, 7IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, Division of Gastroenterology, Foggia, Italy, 8University of Rome "Tor Vergata", Department of Systems Medicine, Rome, Italy

P612: Immunosuppressive co-treatment with infliximab and adalimumab is not superior to anti-TNF monotherapy to prevent treatment failure and treatment discontinuation in ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

S. Vieujean1, E. Louis1, C. Reenaers2*

1CHU Liège, Liège, Belgium, 2CHU Liège, Gastroenterology, Liège, Belgium

P613: Predictors of treatment persistence in ulcerative colitis patients treated with golimumab: A multicentre cohort studyECCO '18 Vienna
Year: 2018
Authors:

G. Biscaglia1, E. Savarino2, A. Variola3, F. Furfaro4, C. Ferracane5, G. Rizzati6, F. Scaldaferri6, G. Mocci7, A. Buda8, A. Privitera5, A. Geccherle3, G. Fiorino9,10*

1IRCSS Casa Sollievo della Sofferenza, Gastroenterology and Digestive Endoscopy Unit, San Giovanni Rotondo, Italy, 2University of Padua, Padua, Italy, 3Sacro Cuore Don Calabria Hospital, Negrar, Italy, 4Humanitas Clinical and Research Institute, IBD Center, Department of Gastroenterology, Rozzano, Italy, 5Cannizzaro Hospital, Catania, Italy, 6Catholic University of Sacred Heart, Internal Medicine and Gastroenterology, Rome, Italy, 7Brotzu Hospital, Gastroenterology Unit, Department of Medicine, Cagliari, Italy, 8S. Maria del Prato Hospital, Gastroenterology and Digestive Endoscopy Unit, Feltre, Italy, 9Humanitas Clinical and Research Institute, Rozzano, Italy, 10Humanitas University, Biomedical Sciences, Rozzano, Italy

P614: Pregnancy outcomes in women with IBD treated with biosimilar infliximabECCO '18 Vienna
Year: 2018
Authors:

M. Kolar1*, D. Duricova1,2, M. Bortlik1,3, M. Lukas1, V. Hruba1, N. Machkova1, K. Malickova1, M. Lukas1,4

1ISCARE I.V.F. a.s., IBD Clinical and Research Centre, Prague, Czech Republic, 21st Medical Faculty, Charles University, Institute of Pharmacology, Prague, Czech Republic, 3Military Hospital, Charles University, Department of Internal Medicine, Prague, Czech Republic, 41st Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry, Prague, Czech Republic

P615: Efficacy of vedolizumab in patients with Crohn's disease may differ depending on the disease location: The UCLH experienceECCO '18 Vienna
Year: 2018
Authors:

T. Kumagai*, M. Vinayaga-Pavan, I. Parisi, J. Barragry, R. Sundramoorthi, L. Whitley, H. Parker, R. Kettle, N. McCabrey, E. Seward, S. McCartney, S. Bloom, R. Vega, S. Mehta, F. Rahman

University College London Hospital, Department of Gastroenterology, London, UK

P616: Utility of zinc protoporphyrin/haem ratio as a marker of iron deficiency with or without anaemia in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

E. Leventi1,2, A. Aksan2,3*, J. Stein1,2, K. Farrag1,2

1DGD Clinics Sachsenhausen, Frankfurt/Main, Germany, 2Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 3Hacettepe University, Faculty of Health Sciences, Ankara, Turkey

P617: Single-centre experience with biological treatment in budesonide-refractory microscopic colitis patientsECCO '18 Vienna
Year: 2018
Authors:

N. Daferera1*, S. Ignatova2, A. Münch3

1Department of Gastroenterology and Hepatology, Linköping, Sweden, 2Department of Pathology, Linköping, Sweden, 3Department of Gastroenterology and Hepatology, Linköping, Sweden